ATC Group: A06AX Other laxatives

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A06AX in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A06 Laxatives
3 A06A Laxatives
4 A06AX Other laxatives

Group A06AX contents

Code Title
A06AX01 Glycerol
A06AX02 Carbon dioxide producing drugs
A06AX03 Lubiprostone

Active ingredients in A06AX

Active Ingredient Description

Glycerol has uses as a hyperosmotic, osmotic diuretic, and ophthalmic agent. It may be used as an eye drop in the treatment of glaucoma to reduce intraocular pressure, as a solution or suppository for short-term treatment of constipation, to evacuate the bowel prior to a colonoscopy, and in some ocular surgeries. It may be given intravenously to reduce pressure inside the brain and used externally on the skin as a moisturizer.


Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans.


Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation (CIC).


Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist. Both plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP).


Prucalopride is a dihydrobenzofurancarboxamide with gastrointestinal prokinetic activities. Prucalopride is a selective, high affinity serotonin (5-HT4) receptor agonist, which is likely to explain its prokinetic effects.


Tegaserod is an agonist of serotonin type-4 (5-HT4) receptors that stimulates the peristaltic reflex and intestinal secretion, inhibits visceral sensitivity, enhances basal motor activity, and normalizes impaired motility throughout the gastrointestinal tract.

Related product monographs

Title Information Source Document Type  
AMITIZA Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
CONSTELLA Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
GLYCERIN BP Liquid Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GLYCERIN Suppository Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
IBSRELA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
RESOLOR Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
RESOTRANS Film-coated tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
ZELNORM Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR